Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Vaccine

Morning Brief: Top Financial Stories Dominating on Wednesday, June 8

CNBC

Benzinga

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Benzinga

Moderna announces promising results from next-generation Covid vaccine trials

Experts hope the newer jabs could protect against a wider range of variants.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna says its new vaccine booster shows 'superior' response to omicron

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

WEKU

Moderna says updated COVID shot boosts omicron protection

Moderna says its experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work

The Independent UK

Moderna Says Omicron-Specific Booster Generates Strong Immune Response

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine. The booster raised virus-neutralizing antibodies by eight-fold in a study.

Asharq Al-Awsat

Moderna says Omicron-targeted COVID shot shows better response

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

Reuters

Read news from The Economist, FT, and more,
with one subscription

COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters

In a telephone interview with Reuters, WTO's Director-General Ngozi Okonjo-Iweala, an agreement on waiving intellectual property rights for COVID-19 vaccines is within reach. A key World Trade Organization (WTO) meeting is scheduled next week to discuss the COVID-19 vaccine patent waiver debate. "If we get one or two deliverables, that…

Benzinga

Breakthrough vaccine could help cure pancreatic cancer

Early trial results suggest personalised vaccines could stop deadly disease returning

The Independent UK

COVID vaccine rights waiver within reach, WTO chief says ahead of meeting

An international agreement on waiving intellectual property rights for COVID-19 vaccines is within reach ahead of a global trade meeting next week, the head of the World Trade Organization said on Wednesday.

Reuters

Covid vaccine technology 'could hold the key to pancreatic cancer cure'

Pancreatic cancer claims 10,000 lives in the UK each year and is the most deadly form of common cancer, with nine out of 10 patients dying within two years of diagnosis

Daily Mirror

Novavax COVID-19 shot gets backing from FDA advisory panel

WASHINGTON — Novavax Inc.’s coronavirus vaccine won the support of a panel of U.S. government advisers, paving the way for authorization of another tool to fight the coronavirus.

Tribune News Service

Can new COVID-19 vaccine win over the anti-vaxxers?

With three COVID-19 vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots.

Tribune News Service

Novavax's COVID-19 Vaccine For Adults Over 18 Backed By FDA Advisors: What's Next?

Novavax, Inc. (NASDAQ: NVAX) announced the U.S.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novavax Shares Gain Following FDA Advisory Committee's Positive Vote On Emergency Use Authorization (EUA) For COVID-19 Vaccine

Novavax’s (NASDAQ: NVAX) COVID-19 vaccine (NVX-CoV2373) receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC), recommending FDA to grant Emergency Use Authorization (EUA) for individuals aged 18 years and over.

WEKU

Advisers to the FDA back Novavax COVID vaccine

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.

Axios

FDA advisers recommend Novavax COVID shot in adults

Officials said Novavax could fill an unmet need because there aren't non-mRNA COVID vaccines that can serve as first line defenses.

The Independent UK

FDA advisers back Novavax COVID-19 shots as new US option

A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

MTG falls for fake Twitter account

The fake account misleadingly tweeted that Pfizer's vaccine has caused widespread miscarriages

Benzinga

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.

Reuters

Bavarian Nordic eyes more monkeypox vaccine orders amid global "wake-up call"

Biotechnology company Bavarian Nordic expects to sign more contracts for its vaccine against monkeypox after "overwhelming" interest from governments around the world, its management told investors on Tuesday.

The Independent UK

Vallance recalls ‘darkest days’ and vaccine that ‘changed course of pandemic’

Sir Patrick Vallance collected an honour from the Duke of Cambridge at Buckingham Palace for helping to lead the UK’s battle against coronavirus.

Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Moderna Commences Late-stage Study of Flu Vaccine Candidate

Moderna, Inc. (NASDAQ: MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza.

Benzinga

J&J Serves Notice To Emergent For Terminating COVID-19 Shot Contract As Two Accuse Each Other Of Breach Of Agreement

Johnson & Johnson (NYSE: JNJ) has made another move towards severing its Covid-19 vaccine manufacturing ties with contract manufacturer Emergent Biosolutions, Inc. (NYSE: EBS).

1 … 272 273 274 275

People

Elon Musk

29,152 stories

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

351 stories

Walmart Inc

251 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.